These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 15531536)

  • 1. Behavioral, adrenal, and sympathetic responses to long-term administration of an oral corticotropin-releasing hormone receptor antagonist in a primate stress paradigm.
    Ayala AR; Pushkas J; Higley JD; Ronsaville D; Gold PW; Chrousos GP; Pacak K; Calis KA; Gerald M; Lindell S; Rice KC; Cizza G
    J Clin Endocrinol Metab; 2004 Nov; 89(11):5729-37. PubMed ID: 15531536
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral administration of a corticotropin-releasing hormone receptor antagonist significantly attenuates behavioral, neuroendocrine, and autonomic responses to stress in primates.
    Habib KE; Weld KP; Rice KC; Pushkas J; Champoux M; Listwak S; Webster EL; Atkinson AJ; Schulkin J; Contoreggi C; Chrousos GP; McCann SM; Suomi SJ; Higley JD; Gold PW
    Proc Natl Acad Sci U S A; 2000 May; 97(11):6079-84. PubMed ID: 10823952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Corticotropin-releasing hormone antagonists, astressin B and antalarmin: differing profiles of activity in rhesus monkeys.
    Broadbear JH; Winger G; Rivier JE; Rice KC; Woods JH
    Neuropsychopharmacology; 2004 Jun; 29(6):1112-21. PubMed ID: 14997174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antalarmin, a putative CRH-RI antagonist, has transient reinforcing effects in rhesus monkeys.
    Broadbear JH; Winger G; Rice KC; Woods JH
    Psychopharmacology (Berl); 2002 Nov; 164(3):268-76. PubMed ID: 12424550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic effects of a nonpeptide corticotropin-releasing hormone type I receptor antagonist on pituitary-adrenal function, body weight, and metabolic regulation.
    Bornstein SR; Webster EL; Torpy DJ; Richman SJ; Mitsiades N; Igel M; Lewis DB; Rice KC; Joost HG; Tsokos M; Chrousos GP
    Endocrinology; 1998 Apr; 139(4):1546-55. PubMed ID: 9528933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of a novel corticotropin-releasing-hormone receptor type I antagonist on human adrenal function.
    Willenberg HS; Bornstein SR; Hiroi N; Päth G; Goretzki PE; Scherbaum WA; Chrousos GP
    Mol Psychiatry; 2000 Mar; 5(2):137-41. PubMed ID: 10822340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic administration of the selective corticotropin-releasing factor 1 receptor antagonist CP-154,526: behavioral, endocrine and neurochemical effects in the rat.
    Arborelius L; Skelton KH; Thrivikraman KV; Plotsky PM; Schulz DW; Owens MJ
    J Pharmacol Exp Ther; 2000 Aug; 294(2):588-97. PubMed ID: 10900236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of the nonpeptide corticotropin-releasing hormone antagonist antalarmin on behavioral and endocrine responses to stress.
    Deak T; Nguyen KT; Ehrlich AL; Watkins LR; Spencer RL; Maier SF; Licinio J; Wong ML; Chrousos GP; Webster E; Gold PW
    Endocrinology; 1999 Jan; 140(1):79-86. PubMed ID: 9886810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A corticotropin-releasing hormone type I receptor antagonist delays parturition in sheep.
    Chan EC; Falconer J; Madsen G; Rice KC; Webster EL; Chrousos GP; Smith R
    Endocrinology; 1998 Jul; 139(7):3357-60. PubMed ID: 9645712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Responses of the sympathetic nervous system and the hypothalamic-pituitary-adrenal axis to interleukin-6: a pilot study in fibromyalgia.
    Torpy DJ; Papanicolaou DA; Lotsikas AJ; Wilder RL; Chrousos GP; Pillemer SR
    Arthritis Rheum; 2000 Apr; 43(4):872-80. PubMed ID: 10765933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of antalarmin, a novel corticotropin-releasing hormone antagonist, on the dynamic function of the preterm ovine fetal hypothalamo-pituitary-adrenal axis.
    Young IR; Chan EC; Smith R; Chrousos GP; Veldhuis JD; Canny BJ
    Neuroendocrinology; 2002 Jul; 76(1):47-54. PubMed ID: 12097816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment with CRH-1 antagonist antalarmin reduces behavioral and endocrine responses to social stressors in marmosets (Callithrix kuhlii).
    French JA; Fite JE; Jensen H; Oparowski K; Rukstalis MR; Fix H; Jones B; Maxwell H; Pacer M; Power ML; Schulkin J
    Am J Primatol; 2007 Aug; 69(8):877-89. PubMed ID: 17397037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of trauma-related audiovisual stimulation on cerebrospinal fluid norepinephrine and corticotropin-releasing hormone concentrations in post-traumatic stress disorder.
    Geracioti TD; Baker DG; Kasckow JW; Strawn JR; Jeffrey Mulchahey J; Dashevsky BA; Horn PS; Ekhator NN
    Psychoneuroendocrinology; 2008 May; 33(4):416-24. PubMed ID: 18295412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does amygdaloid corticotropin-releasing hormone (CRH) mediate anxiety-like behaviors? Dissociation of anxiogenic effects and CRH release.
    Merali Z; Khan S; Michaud DS; Shippy SA; Anisman H
    Eur J Neurosci; 2004 Jul; 20(1):229-39. PubMed ID: 15245495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Coping with chronic social stress in mice: hypothalamic-pituitary-adrenal/ sympathetic-adrenal-medullary axis activity, behavioral changes and effects of antalarmin treatment: implications for the study of stress-related psychopathologies.
    Pérez-Tejada J; Arregi A; Gómez-Lázaro E; Vegas O; Azpiroz A; Garmendia L
    Neuroendocrinology; 2013; 98(1):73-88. PubMed ID: 23796983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activity of the hypothalamic-pituitary-adrenal axis is altered by aging and exposure to social stress in female rhesus monkeys.
    Gust DA; Wilson ME; Stocker T; Conrad S; Plotsky PM; Gordon TP
    J Clin Endocrinol Metab; 2000 Jul; 85(7):2556-63. PubMed ID: 10902808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of CRH in glucopenia-induced adrenomedullary activation in rats.
    Goldstein DS; Garty M; Bagdy G; Szemeredi K; Sternberg EM; Listwak S; Pacak K; Deka-Starosta A; Hoffman A; Chang PC
    J Neuroendocrinol; 1993 Oct; 5(5):475-86. PubMed ID: 8680414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic administration of the non-peptide CRH type 1 receptor antagonist antalarmin does not blunt hypothalamic-pituitary-adrenal axis responses to acute immobilization stress.
    Wong ML; Webster EL; Spokes H; Phu P; Ehrhart-Bornstein M; Bornstein S; Park CS; Rice KC; Chrousos GP; Licinio J; Gold PW
    Life Sci; 1999; 65(4):PL53-8. PubMed ID: 10421433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo and in vitro characterization of antalarmin, a nonpeptide corticotropin-releasing hormone (CRH) receptor antagonist: suppression of pituitary ACTH release and peripheral inflammation.
    Webster EL; Lewis DB; Torpy DJ; Zachman EK; Rice KC; Chrousos GP
    Endocrinology; 1996 Dec; 137(12):5747-50. PubMed ID: 8940412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Altered serotonergic neurotransmission but normal hypothalamic-pituitary-adrenocortical axis activity in mice chronically treated with the corticotropin-releasing hormone receptor type 1 antagonist NBI 30775.
    Oshima A; Flachskamm C; Reul JM; Holsboer F; Linthorst AC
    Neuropsychopharmacology; 2003 Dec; 28(12):2148-59. PubMed ID: 12915860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.